AZD2115

DRUG4 trials

Sponsors

AstraZeneca

Conditions

COPDChronic Obstructive Pulmonary DiseaseHealthyHealthy VolunteersLung Disease Causing Persistent Narrowing of the Airways

Phase 1

AZD2115 Single Ascending Dose Study

CompletedNCT01283984

AstraZenecaChronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways

Start: 2011-01-31End: 2011-08-31Target: 96Updated: 2011-08-18

AZD2115 Multiple Ascending Dose Study

CompletedNCT01445782

AstraZenecaHealthy

Start: 2011-10-31End: 2012-07-31Updated: 2012-10-08

PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium

CompletedNCT03097380

AstraZenecaHealthy Volunteers

Start: 2017-04-26End: 2017-12-30Updated: 2021-08-30

Phase 2

A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

CompletedNCT01498081

AstraZenecaCOPD

Start: 2012-03-31End: 2012-10-31Updated: 2012-10-26

Related Papers

Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans

Frontiers in Nuclear Medicine2023-01-18

Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects

EJNMMI Research2020-06-037 citations